Heinlein Cynthia A, Chang Chawnshang
George Whipple Laboratory for Cancer Research, Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Endocrine. 2003 Jul;21(2):139-46. doi: 10.1385/ENDO:21:2:139.
In an effort to understand transcriptional regulation by the peroxisome proliferator-activated receptor alpha (PPARalpha), we investigated the ability of a number of transcriptional coactivators to enhance PPARalpha:retinoic acid receptor (RXR) mediated transcription. We identified ARA70, a coactivator of the androgen receptor and PPARgamma, as a ligand-enhanced coactivator of PPARalpha in the prostate cancer cell line DU145. In prostate cancer cells, ARA70 demonstrated the strongest enhancement of PPARalpha transcription among the coactivators examined. Mutation of the N-terminal of the PPARalpha ligandbinding domain dramatically reduced the ability of ARA70 to enhance PPARalpha:RXR transcription. ARA70 was able to physically interact with both the wild-type and mutant PPARalpha as determined by coimmunoprecipitation. However, in the adrenal cell line Y1, ARA70 behaved as a repressor of PPARalpha while still able to coactivate PPARgamma.
为了了解过氧化物酶体增殖物激活受体α(PPARα)的转录调控机制,我们研究了多种转录共激活因子增强PPARα:视黄酸受体(RXR)介导的转录的能力。我们在前列腺癌细胞系DU145中鉴定出ARA70,它是雄激素受体和PPARγ的共激活因子,作为PPARα的配体增强型共激活因子。在前列腺癌细胞中,ARA70在所检测的共激活因子中对PPARα转录的增强作用最强。PPARα配体结合域N端的突变显著降低了ARA70增强PPARα:RXR转录的能力。通过免疫共沉淀确定,ARA70能够与野生型和突变型PPARα发生物理相互作用。然而,在肾上腺细胞系Y1中,ARA70表现为PPARα的抑制因子,同时仍能够共激活PPARγ。